Inhibikase Therapeutics
IKT
105 hedge funds and large institutions have $239M invested in Inhibikase Therapeutics in 2026 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 47 increasing their positions, 23 reducing their positions, and 14 closing their positions.
104% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 23
47% more capital inflows, than outflows
Capital inflows: $16.7M | Capital outflows: $11.4M
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
2.05% more ownership
Funds ownership: 87.21% → 89.26% (+2.1%)
1% more funds holding
Funds holding: 104 → 105 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.62M |
| 2 |
Millennium Management
New York
|
+$1.97M |
| 3 |
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$1.78M |
| 4 |
ADAR1 Capital Management
Austin,
Texas
|
+$1.4M |
| 5 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
-$3.89M |
| 2 |
Ally Bridge Group
New York
|
-$2.23M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.84M |
| 4 |
Stonepine Capital Management
Bend,
Oregon
|
-$1M |
| 5 |
Squadron Capital Management
Westmont,
Illinois
|
-$895K |
IKT Hedge Fund Activity: Q2 2026 in Review
105 of the 8,365 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q2 2026, worth a combined $239M — up 24% from $193M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IKT positions and 14 closed out — a net gain of 4 holders — while 47 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $2.62M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $3.89M sold.
- 105 institutional investors held Inhibikase Therapeutics (IKT) as of Q2 2026, up from 104 in Q1 2026.
- Funds reported $239M of Inhibikase Therapeutics stock for Q2 2026, up 24% quarter-over-quarter.
- 18 funds opened new Inhibikase Therapeutics positions in Q2 2026 and 14 closed out, a net change of +4 holders.
- The largest Inhibikase Therapeutics buyer in Q2 2026 was BlackRock, an estimated $2.62M added.
- The largest Inhibikase Therapeutics seller in Q2 2026 was Perceptive Advisors, an estimated $3.89M sold.
Based on aggregated 13F filings for Q2 2026.